Nkarta logo

Nkarta

NKTX | NASDAQ
Chart Builder DCF Calculator
$1.21
+$0.02 (+1.68%)
At close: Nov 16, 2026, 4:00 PM ET
$1.21
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
+1.68%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
29.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #816/1021 (Top 80%)

Key Statistics

Market Data

Market Cap $86.67M
1D Range
1.20 1.28
52W Range
1.19 3.67

Valuation (TTM)

PE -0.70
PB 0.40
EV/EBITDA -0.02

Valuation (NTM)

Forward PE N/A
Forward PEG -0.02
Price Target $9.00
Loading financial charts...

Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a...

Sector Healthcare
Industry Biotechnology
Employees 106
IPO Date Jul 10, 2020
Fiscal Year January - December

Latest News

No news articles available yet.

Analyst Summary

# of Analysts
4
Consensus
Buy
Price Target
$9.00
Upside
+643.80%
Buy (4)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.